Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas Pulls EU Filing for Geographic Atrophy Drug
October 29, 2024
- Astellas Drastically Shaving Research Time with AI Drug Discovery
October 28, 2024
- AbbVie Taps Tiago Campos Rodrigues as Japan President
October 28, 2024
- Chugai Net Profit Jumps to Nearly 300 Billion Yen on Brisk Exports
October 28, 2024
- Recordati to Enter Japan’s Hematology/Oncology Market with Enjaymo Acquisition
October 25, 2024
- Novo Inks Collab Pact with Kasugai City on Obesity Measures
October 25, 2024
- Shionogi-Ube’s Anti-RSV Drug Gets Fast-Track Tag in US
October 25, 2024
- Misako Hamamura to Head Up Alexion Japan from Next Year
October 25, 2024
- Guardant to Close Japan Lab Due to Sluggish Product Uptake
October 24, 2024
- NHI-Market Price Gap Expected to Contract in 2024, Will It Enter Lower 5% Territory?
October 24, 2024
- Otsuka’s IgA Nephropathy Drug Makes Mark in PIII, Eyes Accelerated Path
October 23, 2024
- Tirzepatide Cuts Body Weight in Japanese Adults with Obesity: PIII
October 23, 2024
- CEA Is “Wrong Tool” That Doesn’t Fit into Japanese System: J&J Exec
October 23, 2024
- Takeda to Offer Buyout Package from December as Part of Reorganization
October 22, 2024
- Aculys Pharma’s Pitolisant Nets Positive Data in Japan PIII
October 22, 2024
- Astellas’ Gastric Cancer Med Vyloy Approved in US after Re-Filing
October 22, 2024
- Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
- GSK Japan Targets 8% Average Annual Growth through 2031
October 21, 2024
- Ferring Japan Set for 15% Annual Growth as It Gazes at Gene Therapy Debut
October 21, 2024
- Real-World Data Confirms Efficacy of Cefiderocol in Drug-Resistant Bacteria
October 18, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…